NIMRAD (A Randomised Placebo-controlled Trial of Synchronous NIMorazole Versus RADiotherapy Alone in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Not Suitable for Synchronous Chemotherapy or Cetuximab)

NCT01950689 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

338

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: Nimorazole
RADIATION: Radiotherapy

Sponsor

The Christie NHS Foundation Trust